Plain-English translation of NCT06917911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding or to the standard leukemia treatment combination ( and daunorubicin) works better for younger adults with core binding factor acute myeloid leukemia (a specific type of blood cancer). You would be randomly assigned to receive one of these two treatment combinations. The goal is to see which approach helps more patients achieve complete remission with no remaining cancer cells.
Core binding factor acute myeloid leukemia is a particular subtype of blood cancer, and doctors want to know if adding one of these newer medications to the standard treatment can improve cure rates and how long patients survive.
You likely qualify if…
You likely don't qualify if…
You would receive induction chemotherapy (the initial intensive treatment phase) with either plus the standard drugs, or plus the standard drugs, given intravenously or by mouth over several days. After this initial treatment, you would receive additional standard follow-up chemotherapy decided by your doctor. Throughout the trial, you would have blood tests and bone marrow biopsies to check how well the treatment is working, heart function tests, and may provide optional genetic samples. The study involves close monitoring to watch for side effects and treatment response.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States